Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma

Cell Oncol (Dordr). 2019 Apr;42(2):143-155. doi: 10.1007/s13402-018-0416-2. Epub 2018 Dec 11.

Abstract

Purpose: Emerging evidence indicates that bromodomains comprise a conserved class of epigenome readers involved in cancer development and inflammation. Bromodomains are associated with epigenetic modifications of gene transcription through interactions with lysine residues of histone tails. Particularly, the bromodomain and extra-terminal domain (BET) family member BRD4 has been found to be involved in the control over oncogenes, including c-MYC, and in the maintenance of downstream inflammatory processes. The objective of this study was to evaluate the effect of pharmacologically displacing BRD4 in mucoepidermoid carcinoma (MEC) cells.

Methods: We assessed the presence of BRD4 levels in a panel of human MEC tissue samples in conjunction with histological grading and clinical information. In vitro studies were carried out using human MEC-derived cell lines. The BET inhibitor iBET762 was administered to MEC cells to assess the impact of disrupted BRD4 signaling on colony forming capacities and cell cycle status. The activation of cellular senescence induced by iBET762 was determined by immunohistochemical staining for p16ink4. Flow cytometry was used to identify populations of cancer stem cells in MEC-derived cell lines.

Results: We found that primary human MECs and MEC-derived cell lines are endowed with high BRD4 expression levels compared to those in normal salivary glands. We also found that, by displacing BRD4 from chromatin using the BET inhibitor iBET762, MEC cells lose their colony forming capacities and undergo G1 cell cycle arrest and senescence. Finally, we found that targeted displacement of BRD4 from chromatin results in depletion of cancer stem cells from the overall MEC cell populations.

Conclusions: Our findings indicate that bromodomain-mediated gene regulation constitutes an epigenetic mechanism that is deregulated in MEC cells and that the use of BET inhibitors may serve as a feasible therapeutic strategy to manage MECs.

Keywords: BRD4; Cancer stem cells; Epi-drug; Epigenetic; Mucoepidermoid carcinoma; iBET762.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Benzodiazepines / pharmacology
  • Carcinoma, Mucoepidermoid / drug therapy*
  • Carcinoma, Mucoepidermoid / genetics*
  • Carcinoma, Mucoepidermoid / pathology
  • Cell Cycle Proteins
  • Cell Line, Tumor
  • Cellular Senescence / drug effects
  • Epigenesis, Genetic* / drug effects
  • Female
  • Histones / metabolism
  • Humans
  • Male
  • Middle Aged
  • Models, Biological
  • Molecular Targeted Therapy*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology
  • Nuclear Proteins / metabolism
  • Signal Transduction / drug effects
  • Transcription Factors / metabolism
  • Tumor Stem Cell Assay
  • Young Adult

Substances

  • BRD4 protein, human
  • Cell Cycle Proteins
  • Histones
  • Nuclear Proteins
  • Transcription Factors
  • Benzodiazepines
  • molibresib